A Curve‐Free Method for Phase I Clinical Trials
From MaRDI portal
Publication:4667490
DOI10.1111/j.0006-341X.2000.00609.xzbMath1060.62611OpenAlexW2080277472WikidataQ52076810 ScholiaQ52076810MaRDI QIDQ4667490
Jeffrey R. Eisele, Mauro Gasparini
Publication date: 20 April 2005
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.0006-341x.2000.00609.x
dose-finding studiesmaximum tolerated dosephase I clinical trialcontinual reassessment methodtoxicityneutral to the right processproduct-of-beta priors
Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian inference (62F15)
Related Items (20)
Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data ⋮ An application of reinforced urn processes to determining maximum tolerated dose ⋮ A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents ⋮ Impact of different model structure and prior distribution in continual reassessment method ⋮ Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials ⋮ Stochastic approximation and modern model-based designs for dose-finding clinical trials ⋮ Continual reassessment and related dose-finding designs ⋮ Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control ⋮ Adaptive clinical trial designs for phase I cancer studies ⋮ Design efficiency in dose finding studies ⋮ The treatment versus experimentation dilemma in dose finding studies ⋮ On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance ⋮ Curve-Free and Model-Based Continual Reassessment Method Designs ⋮ A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method ⋮ Bayesian Optimal Designs for Phase I Clinical Trials ⋮ EM-type algorithms for computing restricted MLEs in multivariate normal distributions and multivariatet-distributions ⋮ Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials ⋮ A comparative study of the dose-response analysis with application to the target dose estimation ⋮ Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials ⋮ Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- On the distribution of the product of independent beta random variables
- A Bayesian nonparametric approach to determining a maximum tolerated dose
- Tailfree and neutral random probabilities and their posterior distributions
- Continual Reassessment Method: A Likelihood Approach
This page was built for publication: A Curve‐Free Method for Phase I Clinical Trials
